SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AstraZeneca completes exclusive license deal for ZEGFROVY

AstraZeneca (AZN) announced the successful completion of its previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY (sunvozertinib), an oral irreversible EGFR inhibitor for lung cancer patients.

AZN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories